Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 321 patients, newly diagnosed with PTCL-NOS (n = 180) or AITL (n = 141) between 1999 and 2015, were analysed.
|
27983760 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The miRNA profile of PTCLs/NOS then was compared with that of 10 angioimmunoblastic T-cell lymphomas (AITLs), 6 anaplastic large-cell lymphomas (ALCLs)/ALK+ and 6 ALCLs/ALK-.
|
25382608 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, a novel recurring somatic mutation in RHOA, encoding p.Gly17Val, was discovered in nearly 70% of AITLs and in a smaller proportion of peripheral T-cell lymphomas, not otherwise specified (PTCL-NOS).
|
26574844 |
2016 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
First-line CHOP and CHOP-like regimens were used in 74% of patients, providing 4-year overall survival (OS) outcomes of 34% (95% confidence interval [CI], 14%-83%) in patients without transplant consolidation (82% in ALCL, 37% in PTCL-NOS, and 0% in AITL).
|
28622960 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent identification of follicular helper T (T(FH)) cell as the cell of origin of this neoplasm represents a major step in our understanding of the pathobiological characteristics of the disease and should, in the future, clarify the diagnostic criteria for AITL and help to delineate its spectrum, especially from PTCL, not otherwise specified (PTCL, NOS).
|
19961485 |
2010 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
This method could serve as a novel diagnostic tool for 60-70% of AITL and AITL-like PTCL-NOS.
|
25310466 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate that B-cell clonality is a common finding in AILT and PTCL-NOS, and its presence should not negate the diagnosis established by morphologic, immunophenotypic, and clinical findings.
|
16931587 |
2006 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two residues-D124 and T195-were recurrently mutated in 11.3% of cases of AITL and in one case of PTCL, not otherwise specified (PTCL-NOS).
|
26719098 |
2016 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In total, 97 patients with AITL (n=37), PTCL-NOS (n=40), ALK-negative ALCL (n=11), or ALK-positive ALCL (n=9) were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).
|
29100307 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Gene expression profiling (GEP) defined molecular signatures for AITL and delineated biological and prognostic subgroups within PTCL-NOS (PTCL-GATA3 and PTCL-TBX21).
|
30782609 |
2019 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples.
|
24413734 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The RHOA G17V mutation was found in 15 (75%) of 20 AITL and two (22%) of nine PTCL, NOS.
|
31394087 |
2019 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We correlated EBV localization with clinicopathologic findings in PTCL-NOS (n = 63) and AITL (n = 26).
|
24180328 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among PTCL-NOS, a heterogeneous group of lymphoma-comprising cases likely to derive from Th follicular (T(FH)) cells similarly to AITL, TET2 mutations were more frequent when PTCL-NOS expressed T(FH) markers and/or had features reminiscent of AITL (58% vs 24%, P = .01).
|
22760778 |
2012 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, BCL-6 expression was the only T<sub>FH</sub> marker differentially expressed between AITL and PTCL-NOS cases.
|
29662631 |
2018 |
Angioimmunoblastic Lymphadenopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTCL-NOS shared a similar pattern of ITK and SYK gains with AITL.
|
25337257 |
2014 |